Laboratories Daffodil Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 27-12-2024
- Paid Up Capital ₹ 1.20 M
as on 27-12-2024
- Company Age 43 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
as on 27-12-2024
- Revenue 6.53%
(FY 2023)
- Profit 206.24%
(FY 2023)
- Ebitda -213.59%
(FY 2023)
- Net Worth 1.35%
(FY 2023)
- Total Assets 5.45%
(FY 2023)
About Laboratories Daffodil
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹2.50 M.
Sanjay Shanbhag and Seema Shanbhag serve as directors at the Company.
- CIN/LLPIN
U99999MH1981PTC024104
- Company No.
024104
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 1981
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationMumbai, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Laboratories Daffodil?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Shanbhag  | Managing Director | 01-Apr-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Seema Shanbhag | Director | 14-Dec-2020 | Current |
Financial Performance of Laboratories Daffodil.
Laboratories Daffodil Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.53% increase. The company also saw a substantial improvement in profitability, with a 206.24% increase in profit. The company's net worth moved up by a moderate rise of 1.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Laboratories Daffodil?
Unlock access to Laboratories Daffodil's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 14 Jan 2004 | ₹2.50 M | Open |
How Many Employees Work at Laboratories Daffodil?
Laboratories Daffodil has a workforce of 45 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Laboratories Daffodil, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Laboratories Daffodil's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
